Merck Drug Lifts Survival in 473-Patient Trial, Misses Secondary Goal

Merck said on Nov 20, 2026 that its experimental cancer drug sacituzumab tirumotecan, or sac-TMT, helped patients with advanced gastroesophageal adenocarcinoma live longer than standard chemotherapy in a global phase 3 trial. The trial, called TroFuse-015, enrolled 473 patients. It did not, however, show a benefit on a secondary measure of how long patients lived without their cancer getting worse.
What happened
TroFuse-015 tested sac-TMT in adults whose cancer had already progressed after at least 2 earlier lines of treatment. The cancer started in the stomach, the junction with the esophagus, or the esophagus itself. Patients were randomly assigned to sac-TMT or to a chemotherapy chosen by their doctor.
- Comparison: the doctor's choice was trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel, according to BioPharm International.
- Dosing: sac-TMT was given at 4 mg/kg on days 1, 15 and 29 of each 6-week cycle, CancerNetwork reported.
- Main goal met: Merck said the drug produced a statistically significant and clinically meaningful gain in overall survival at the final analysis.
- Second goal missed: progression-free survival, judged by a blinded independent central review, was not met.
- Response rate: it leaned toward sac-TMT but was not formally tested under the trial's plan.
Merck did not release a hazard ratio or median survival figures. The company said the detailed results will be presented at an upcoming medical meeting and shared with regulators. The safety profile matched earlier studies of the drug, with no new safety signals, the company said.
Why it matters
Marjorie Green leads oncology clinical development at Merck Research Laboratories. She said sac-TMT is the first TROP2-directed antibody drug conjugate to improve survival against doctor's choice therapy in a global phase 3 study in this cancer. The survival benefit was generally consistent whether or not tumours expressed TROP2, according to CancerNetwork. Patients did not need TROP2 expression to join the trial.
The drug was developed by Kelun-Biotech, which gave Merck exclusive rights outside Greater China. This is the second positive phase 3 result in Merck's TroFuse program for the drug. Merck is running 18 global phase 3 trials of the drug in more than 15,000 patients.
The other positive TroFuse trial was in endometrial cancer. In that study, median overall survival was 19.0 months with sac-TMT against 12.1 months with chemotherapy. The FDA has accepted Merck's application in that use, with a target action date of June 15, 2027.
What it means for people in the industry
BioPharm International noted that the trial was open label and that the results are topline only and not peer reviewed. It also said no regulatory filing in this cancer has been announced. The full numbers, due at a medical meeting, will show how large the survival gain is.
See open pharma jobs in the US and Canada
Sources
- Merck TROP2 ADC Meets Survival End Point in Gastroesophageal Cancer, BioPharm International
- Sac-TMT Meets OS End Point in Pretreated Gastroesophageal Adenocarcinoma, CancerNetwork
Check Your Supplement Interactions
Use our AI-powered checker to analyze supplement safety and interactions.
Open Interaction Checker →Comments (0)
This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.